Cytokinetics (CYTK) Stock Price, News & Analysis

Company Overview

Cytokinetics, Inc. is a late‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.

The company’s most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility. In parallel, Cytokinetics has advanced reldesemtiv, a skeletal muscle activator, into clinical development for neuromuscular disorders such as amyotrophic lateral sclerosis and spinal muscular atrophy. A third key program, apitegromab, seeks to preserve and restore muscle function in patients with muscle‐wasting diseases by inhibiting myostatin activation. Beyond these lead assets, Cytokinetics maintains a pipeline of early‐stage candidates targeting both cardiac and skeletal muscle biology.

While based in the United States, Cytokinetics conducts clinical trials across North America, Europe and Asia, and has forged strategic collaborations with major biopharmaceutical firms to support global development and commercialization. Led by a management team with extensive experience in drug discovery, clinical development and regulatory affairs, the company continues to expand its scientific platform and pursue strategic partnerships. Through its targeted approach to muscle biology, Cytokinetics seeks to bring new therapeutic options to patients suffering from debilitating cardiac and neuromuscular diseases.

Key Stats

• Today's Range: $73.00 to $76.78
• 50-Day Range: $59.58 to $78.64
• 52-Week Range: $29.81 to $80.20
• Volume: 2.40 million shs
• Average Volume: 2.24 million shs
• Market Capitalization: $9.51 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $99.30
• Consensus Rating: Moderate Buy

Cytokinetics Stock Analysis - MarketRank™

Cytokinetics scored higher than 59% of companies evaluated by MarketBeat, and ranked 391st out of 851 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Cytokinetics has received a consensus rating of Moderate Buy. The company's average rating score is 2.82, and is based on 1 strong buy rating, 17 buy ratings, 3 hold ratings, and 1 sell rating.

Upside Potential

Cytokinetics has a consensus price target of $99.30, representing about 29.9% upside from its current price of $76.45.

Amount of Analyst Coverage

Cytokinetics has been the subject of 15 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Cytokinetics are expected to grow in the coming year, from ($6.26) to ($4.58) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Cytokinetics is -11.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Cytokinetics is -11.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

13.12% of the float of Cytokinetics has been sold short.

Short Interest Ratio / Days to Cover

Cytokinetics has a short interest ratio ("days to cover") of 9.68.

Change versus previous month

Short interest in Cytokinetics has recently increased by 6.79%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Cytokinetics does not currently pay a dividend.

Dividend Growth

Cytokinetics does not have a long track record of dividend growth.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 0.54

News Sentiment

Cytokinetics has a news sentiment score of 0.54. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.39 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 16 news articles for Cytokinetics this week, compared to 14 articles on an average week.

Search Interest

Only 7 people have searched for CYTK on MarketBeat in the last 30 days. This is a decrease of -13% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Cytokinetics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $11,294,769.00 in company stock.

Percentage Held by Insiders

2.60% of the stock of Cytokinetics is held by insiders.

Percentage Held by Institutions

Cytokinetics has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 5/05/2026
• Today: 5/19/2026
• RBC Capital Markets Global Healthcare Conference 2026: 5/19/2026
• Next Earnings (Estimated): 8/06/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CYTK
• CIK: 1061983
• Web: www.cytokinetics.com
• Phone: (650) 624-3000
• Fax: 650-624-3010
• Employees: 250
• Year Founded: 1998

Price Target and Rating

• Average Price Target for Cytokinetics: $99.30
• High Price Target: $140.00
• Low Price Target: $56.00
• Potential Upside/Downside: +29.9%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.82
• Research Coverage: 22 Analysts

Profitability

• EPS (Trailing Twelve Months): ($6.84)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$784.96 million
• Net Margins: -784.02%
• Pretax Margin: -784.02%
• Return on Equity: N/A
• Return on Assets: -52.86%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.21
• Quick Ratio: 4.21

Sales & Book Value

• Annual Sales: $88.04 million
• Price / Sales: 108.05
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($5.39) per share
• Price / Book: -14.18

Miscellaneous

• Outstanding Shares: 124,430,000
• Free Float: 121,198,000
• Market Cap: $9.51 billion
• Optionable: Optionable
• Beta: 0.38